Related by context. All words. (Click for frequent words.) 76 blinded placebo controlled 76 double blind placebo 76 blind randomized placebo 75 blind randomized 75 placebo controlled 74 randomized double 74 randomized placebo controlled 72 randomized controlled 69 masked placebo controlled 68 multicenter 66 blind multicenter 66 prospective randomized 66 randomized 65 multicentre 65 multicenter randomized double 65 dose escalation study 65 controlled multicenter 65 placebo controlled Phase 65 safety tolerability pharmacokinetics 64 blinded randomized placebo controlled 64 randomized clinical 64 multicenter randomized 64 placebo controlled randomized 64 dose escalation trial 64 randomized multicenter 64 safety tolerability 64 placebo controlled clinical 64 placebo controlled Phase III 63 Phase 1b clinical 63 Phase III randomized 63 blind randomized controlled 63 multicentre randomized double 63 label dose escalation 63 single ascending dose 63 blind placebo 62 multicenter study 62 randomized controlled trial 62 controlled dose escalation 62 dose dose escalation 62 double blinded randomized 62 multicenter randomized placebo controlled 61 pivotal Phase III 61 label multicenter 61 ascending dose 61 placebo controlled dose escalation 61 TMC# C# 61 ascending doses 61 pharmacodynamics 60 multicentre randomized 60 Phase 2b study 60 symptomatic BPH 60 prospective randomized controlled 60 active comparator 60 prospective cohort 60 randomized controlled clinical 60 prospective observational 60 Phase 2b clinical 59 pharmacokinetics PK 59 tolerability 59 Phase IIb trial 59 treatment naïve genotype 59 pharmacokinetics 59 multicenter multinational 59 placebo controlled studies 59 blinded randomized 59 Phase 2a clinical 59 treatment naive genotype 59 Phase 1b trial 59 Phase 1b 59 pivotal Phase 59 dose escalation Phase 58 Phase Ib 58 randomized Phase III 58 Phase III clinical 58 multicenter Phase III 58 multicenter prospective 58 double blinded placebo 58 Phase Ib clinical 58 multicenter Phase II 58 multicenter randomized controlled 58 randomized #:# 58 prospective multicenter 57 dose escalation 57 safety tolerability pharmacokinetic 57 phase Ib 57 Phase 1a 57 Phase IIa clinical 57 XIENCE V Stent System 57 Phase IIb 57 TG MV 57 Sorafenib HCC Assessment 57 multiple ascending dose 57 phase IIb clinical 57 placebo controlled trials 57 multicenter clinical 57 dose escalation clinical 57 Phase III clinical trials 57 Phase 2b trial 57 RG# ITMN 57 clinical trial 56 Phase IIa 56 randomized multicenter trial 56 observer blinded randomized 56 Phase IIIb 56 Phase IIa trial 56 AIR CF1 56 COMFORT II 56 PRECiSE 56 phase IIa 56 RE LY ® 56 Phase Ia 56 mg BID 56 multicentre study 55 randomized multicentre 55 mg administered orally 55 #mg/day [001] 55 pegylated interferon alfa 2a 55 Phase 2b 55 #mg BID [001] 55 Phase III placebo controlled 55 label dose titration 55 ACTEMRA TM 55 Phase IIIb clinical 55 multinational multicenter randomized 55 phase IIa clinical 55 diabetic neuropathic pain 55 tolerability pharmacokinetics 55 dyskinesia PD LID 55 NO# [002] 55 label multicenter Phase 55 Phase IIb clinical 55 prospective randomized multicenter 55 relapsed MM 55 placebo controlled clinical trials 55 Study ADX# 55 blind randomized multicenter 55 recurrent malignant glioma 55 CRESTOR #mg 55 de novo kidney transplant 55 CTA# Injection 55 patients undergoing percutaneous 55 dose cohorts 55 EQUIP OB 55 multicenter Phase 55 nonrandomized 55 telaprevir dosing 55 ABSORB clinical 55 comparing XIENCE V 55 retrospective cohort study 54 HCV SPRINT 54 landmark ATHENA 54 randomized Phase 54 dosing cohorts 54 BRIM2 54 dabigatran etexilate 54 tolerated dose MTD 54 Phase 2a trial 54 null responder HCV 54 randomized controlled multicenter 54 ARIXTRA 54 mg dose 54 phase IIb 54 CLARITY study 54 evaluating REVLIMID 54 non inferiority 54 substudy 54 blind multicentre 54 randomized controlled trials 54 relapsing remitting multiple sclerosis 54 dose regimens 54 viral kinetic 54 Initiated Phase 54 trials RCTs 54 dose regimen 54 peginterferon alfa 2b 54 prospective multicenter randomized 54 HCV RESPOND 2 54 dose escalation phase 54 Phase III pivotal 54 primary hypercholesterolemia 54 TAXUS ATLAS 54 LEXIVA r 54 ZYBRESTAT fosbretabulin 54 relapsing multiple sclerosis 54 multicenter placebo controlled 54 LUX Lung 54 PREZISTA r 54 pharmacodynamic profile 54 mg QD 54 Randomized controlled 53 prospective randomized placebo 53 randomized clinical trials 53 Phase IIIb study 53 #mg QD [002] 53 Phase III 53 phase 2a 53 PRE SURGE 53 INSPIRE Trial Phase III 53 Phase Ib IIa 53 randomized controlled Phase 53 EQUATE OB 53 relapsed refractory multiple myeloma 53 sunitinib malate 53 recurrent glioblastoma multiforme 53 comparator arm 53 receiving INTRON 53 dose placebo controlled 53 EDEMA3 53 multicenter phase 53 weekly subcutaneous injections 53 phase Ib clinical 53 VICTOR E1 53 μg dose 53 pegylated interferon alfa 2b 53 REALITY Trial 53 randomized controlled clinical trials 53 SPIRIT III 53 Carotid Revascularization Endarterectomy vs. 53 RoACTEMRA 53 phase III ACCLAIM 53 investigational oral 53 oral deforolimus 53 Phase #/#a 53 posaconazole 53 venlafaxine XR 53 registrational 53 Randomised 53 longitudinal cohort study 53 randomized crossover 53 Phase III multicenter 53 AIR CF2 53 GetGoal Phase III 53 dirucotide MBP# 53 e HEALING 53 designated HVTN 53 naïve HCV 53 monotherapy 53 placebo controlled multicenter 53 refractory CLL 53 adult chronic ITP 53 BRIM3 53 confirmatory Phase III 52 CIMZIA TM certolizumab pegol 52 prospective nonrandomized 52 administered subcutaneously 52 multicenter randomized clinical 52 randomized blinded 52 multicentre randomized controlled 52 retrospective observational study 52 hyperphenylalaninemia HPA due 52 metastatic HRPC 52 plus dexamethasone 52 XIENCE V demonstrated 52 Phase 2b randomized 52 Pivotal Trial 52 DAPT 52 teriflunomide 52 Traficet EN 52 desvenlafaxine succinate 52 RSD# oral 52 CATIE AD 52 PEGINTRON TM 52 Phase 2a 52 FAME Study 52 IBS C 52 oral rivaroxaban 52 ANCHOR trial 52 Pegasys ® 52 RRMS patients 52 ragweed allergic 52 pharmacokinetic 52 lubiprostone 52 forodesine 52 zonisamide SR 52 post herpetic neuralgia PHN 52 acute coronary syndromes ACS 52 maximally tolerated dose 52 Raptiva r 52 sequential dose escalation 52 chronic HCV infection 52 nab paclitaxel 52 mg TID 52 CAMMS# 52 mg RDEA# 52 registrational Phase 52 analgesic efficacy 52 RG# [001] 52 plus ribavirin 52 heFH 52 Proellex TM 52 evaluable patients 52 Edge STudy 52 ascending dose study 52 investigational drug 52 MAGE A3 ASCI 52 cilostazol 52 oral FTY# 52 Primary endpoints 52 primary endpoint 52 retrospective cohort 52 randomized Phase IIb 52 beta2 agonist 52 Randomized 52 sorafenib tablets 52 TMC# [001] 52 PEG INTRON R 52 EURIDIS 52 observational cohort study 52 oral ridaforolimus 52 APPRAISE 52 8mg/kg 52 HeFH 51 observational cohort 51 novel VDA molecule 51 Dacogen injection 51 Phase Ib II 51 plus prednisone 51 prospective multicentre 51 randomized trials 51 intra articular injection 51 RECORD1 51 OLYMPIA registry 51 #:# randomization 51 Oral NKTR 51 Navelbine 51 dosage regimens 51 stable angina pectoris 51 evaluating Xcytrin 51 recurrent glioma 51 CIMZIA ™ 51 mcg albinterferon alfa 2b 51 By JENNIFER LEARN 51 ADVANCE PD 51 IFN alfa 51 TYGACIL 51 EVEREST II 51 riociguat 51 GAMMAGARD 51 LITHE 51 efavirenz EFV 51 COPEGUS ribavirin 51 trial evaluating PRX# 51 lexidronam injection 51 EchoCRT 51 APEX PD 51 non valvular atrial 51 pharmacodynamics PD 51 non splenectomized 51 CYPHER R stent 51 q8h 51 thorough QT 51 Val HeFT 51 phase IIIb 51 #mg/m# [001] 51 phase IIb study 51 APTIVUS 51 pegylated interferon 51 prospectively defined 51 mcg kg 51 Myocardial Infarction Study 51 relapsing remitting MS RRMS 51 relapsed myeloma 51 blinded randomized controlled 51 Betaferon ® 51 postmenopausal osteoporotic women 51 inhalations twice 51 DPNP 51 plus Copegus R 51 PRX # 51 evaluating tivozanib 51 AIR CF3 51 number NCT# ClinicalTrials.gov 51 Phase III Pivotal 51 Pentacel R 51 aflibercept VEGF Trap 51 pharmacologically active isomer 51 CONQUER OB 51 DLTs 51 melphalan prednisone 51 ENESTnd 51 Zenvia ™ 51 subcutaneously administered 51 blinded placebo 51 protease inhibitor PI 51 PEG PAL 51 docetaxel Taxotere R 51 ARCOXIA 51 rosuvastatin 51 rALLy clinical trial 51 CIMZIA TM 51 PD LID 51 Randomized Double blind 51 TRANSFORMS 51 TYKERB 51 ADMIRE HF 51 BoNTA 51 Phase III trials 51 Randomized Phase 51 PROMACTA 51 ritonavir boosted atazanavir 51 NOXAFIL 51 observational study 51 glatiramer acetate 51 interferon gamma 1b 51 CERVARIX 51 atherothrombotic events 51 REVIVE Diabetes 51 EmbraceAC 51 Prospective Randomized 51 metastatic hormone refractory 51 Intervention Effectiveness 51 VIRAMUNE XR 51 ACTEMRA 51 multicentre prospective 51 AZX# 51 REMINYL ® 51 composite endpoint 51 hyperlipidemic 51 3TC lamivudine Epivir 51 SEROQUEL 51 NATRECOR ® 51 daily Infergen 51 prucalopride 51 ribavirin RBV 50 DU #b 50 Endeavor Resolute DES 50 IIIa inhibitor 50 HCV infected 50 stage IIIB 50 plus gemcitabine 50 hypogonadal men 50 REYATAZ r 50 ritonavir boosted 50 eculizumab 50 APTIVUS r 50 telaprevir dosed 50 pharmacokinetic PK 50 peginterferon alfa 2a 50 Phase Ib clinical trials 50 GEM OS1 50 subanalysis 50 randomized blinded placebo 50 VELCADE melphalan 50 CANCIDAS 50 bosentan 50 pharmacokinetic profile 50 TAXUS VI 50 INCB# [003] 50 PREZISTA ritonavir 50 somatostatin analog 50 phase IIb trial 50 TMC# r 50 Randomized Evaluation 50 Parkinson disease levodopa induced 50 plus COPEGUS 50 nitazoxanide 50 ug dose 50 ORMD 50 Secondary endpoints 50 prospectively randomized 50 Pharmacokinetics PK 50 MEND CABG 50 STRIDE PD 50 mcg doses 50 Methylnaltrexone 50 pharmacokinetic PK study 50 severe oral mucositis 50 catheter occlusion 50 label multicenter randomized 50 Staccato prochlorperazine 50 etanercept 50 pharmacodynamic 50 ONTARGET 50 dexpramipexole 50 Microplasmin 50 Omacetaxine mepesuccinate 50 RESOLUTE 50 Tolvaptan 50 dose cohort 50 LibiGel Phase III 50 primary generalized tonic 50 low dose cytarabine 50 iloprost synthetic compound 50 ExTRACT TIMI 50 dosing regimens 50 Phase 1a clinical 50 fenofibric acid 50 multicenter dose escalation 50 oral prodrug 50 imetelstat GRN#L 50 mcg dose 50 peg IFN 50 registrational trial 50 bile duct tumor 50 knee osteoarthritis OA 50 nucleoside analog 50 noninferiority 50 HOPE TOO 50 COU AA 50 RE SURGE 50 glucocorticoid induced osteoporosis 50 headache nasopharyngitis 50 mg kg dose 50 Multicenter 50 HIV HCV coinfected 50 relapsing remitting MS 50 Diabetic Macular Edema DME 50 PRTX 50 chronic ITP patients 50 TBC# 50 mg/m2 dose 50 KAPIDEX 50 Phase IIb III 50 rapid virologic response 50 intravenous dosing 50 IIa trial 50 rheumatoid arthritis psoriatic arthritis 50 antiretroviral naive 50 mg/m2 50 pharmacokinetic studies 50 Placebo controlled 50 tanespimycin 50 dosing cohort 50 Angiox R 50 Imprime PGG 50 coadministration 50 mixed hyperlipidemia 50 confirmatory Phase 3 50 Clinical Antipsychotic Trials 50 pain palliation 50 Allovectin 7 ® 50 #mg dose [001] 50 Tarceva TM 50 dose pharmacokinetic 50 Teriflunomide 50 PSN# [002] 50 HCV genotype 1 50 CURRENT OASIS 7 50 Phase #b/#a 50 complement inhibitor eculizumab 50 Neovascular AMD 50 velafermin 50 subcutaneous methylnaltrexone 50 thymalfasin 50 mg doses 50 STELARA 50 peginterferon alfa 50 abacavir lamivudine 50 rhIGF-I/rhIGFBP-3 50 EXPLORE Xa 50 partial onset seizures 50 hypoparathyroidism 50 Randomized Double Blind Placebo 50 ORENCIA ® 50 ENDEAVOR IV 50 quinacrine 50 AA Amyloidosis 50 Sapacitabine 50 antiretroviral naïve 50 CYPHER R Sirolimus eluting 50 pharmacodynamic effects 50 REYATAZ r arm 50 paclitaxel eluting stents 50 fallopian tube cancers 50 secondary efficacy endpoints 50 opioid induced bowel dysfunction 50 subcutaneous doses 50 Diamyd ® 50 alfa 2a 50 humanized interleukin 6 50 recurrent genital herpes 50 atazanavir ritonavir 50 PRoFESS 50 mcg BID 50 MGd 50 tapentadol ER 50 catheter occlusion CO 50 6R BH4 50 #mg q8h 50 dose limiting toxicities 50 CYPHER R Stent 50 vicriviroc 50 Engerix B 50 clinical pharmacology studies 49 intermittent claudication 49 RELOVAIR ™ 49 BOLDER II 49 FASLODEX 49 Hsp# Inhibitor 49 constipation OIC 49 TCAD therapy 49 diagnosed Ph + 49 intermittent dosing 49 intravitreal injection 49 R# #mg BID 49 mixed dyslipidemia 49 postmenopausal women 49 mGluR5 NAM 49 stage IIIb IV 49 Phase III Clinical Trial 49 IIa clinical 49 CML CP 49 lopinavir r arm 49 systemic juvenile idiopathic 49 visilizumab 49 GATTEX ™ 49 SYNTAX trial 49 Cannabinor 49 acyclovir Lauriad R 49 vapreotide acetate 49 DAPT Study 49 KRN# 49 Maximum Tolerated Dose MTD 49 Folfox 49 chlorambucil 49 dose titration 49 Aplidin R 49 Thrombolysis 49 lomitapide 49 TEAEs 49 NP2 Enkephalin 49 evaluating MGCD# [002] 49 ATACAND 49 Phase Ib study 49 GSK# [001] 49 mcg kg REBETOL 49 opioid naive 49 prescribed atypical antipsychotic 49 FFNS 49 Phase 2b kidney transplant 49 Peg IFN 49 CK # 49 ongoing Phase 1b 49 NCT# 49 SCH # 49 icatibant 49 NCCTG 49 Polyp Prevention Trial 49 acute PAO 49 oxycodone CR 49 Chronic Idiopathic Constipation 49 adalimumab 49 prasterone 49 risperidone Risperdal 49 heavily pretreated 49 specific CCR9 antagonist 49 ankylosing spondylitis AS 49 Phase 2b dose 49 bevirimat Study 49 PEG Interferon lambda 49 Prostate Lung Colorectal 49 Aryplase 49 ALN TTR# 49 bepotastine besilate nasal spray 49 BR.# 49 nucleoside naive 49 pharmacodynamic PD 49 atorvastatin Lipitor 49 NGX# 49 PRIMO CABG 49 nulliparous women 49 boosted protease inhibitor 49 VNP#M 49 randomized discontinuation trial 49 estramustine 49 unique alkylating agent 49 OPT CHF 49 unstable angina UA 49 venous thromboembolic events 49 ZACTIMA 49 serotonin norepinephrine reuptake inhibitor 49 peginterferon alfa 2a #KD 49 Androxal TM 49 PEG INTRON 49 NOXAFIL Oral Suspension 49 rFVIIIFc 49 reslizumab 49 Degarelix 49 Cloretazine 49 controlled multicenter Phase 49 sirolimus eluting stent 49 bupropion SR 49 ALN VSP Phase 49 CYPHER ® Stent 49 randomized #:#:# 49 Trial Evaluating 49 IMPACT DCM trial 49 Combination REOLYSIN R 49 GATTEX ® 49 Multiple Ascending Dose 49 CLL8 49 autoantibody positive 49 evaluating Actimmune 49 immunogenicity 49 adjunctive placebo 49 REBETOL 49 cetrorelix pamoate 49 Atherosclerosis MESA 49 non constipating irritable 49 MIRAPEX 49 recurrent metastatic 49 AEG# 49 cisplatin gemcitabine 49 claudication 49 biliary tract cancer 49 bendamustine 49 brivaracetam 49 iobenguane 49 thetreatment 49 REYATAZ ritonavir 49 R#/MEM # 49 NSABP B 49 DP b# 49 Multi Ethnic Study 49 evaluable 49 Phase #b/#a clinical 49 randomized discontinuation 49 Phase 1b dose escalation 49 Major Depressive Disorder MDD 49 Swedish Mammography Cohort 49 lintuzumab SGN 49 daunorubicin 49 acute mania 49 bazedoxifene conjugated estrogens 49 secondary efficacy endpoint 49 INTEGRILIN R 49 INCB# [001] 49 Diabetic Macular Edema 49 HORIZONS AMI trial 49 Pegasys plus Copegus 49 Communities ARIC study 49 cell lymphoma CTCL 49 quadrivalent HPV vaccine 49 TAXUS IV 49 Professionals Follow 49 tgAAC# 49 pimecrolimus cream 49 oral ribavirin 49 Phase IIa trials 49 XIENCE V PROMUS Stent 49 lacosamide 49 teduglutide 49 intravenous picoplatin 49 #mg/m# [002] 49 intravenous belinostat 49 histologically confirmed 49 azilsartan medoxomil 49 AzaSite Plus 49 Dose Ranging Study 49 mcg 49 Phase #b/#a trial 49 COPAXONE R 49 CCR5 tropic HIV 49 RE LY 49 4mg/kg 49 PEGINTRON 49 APEX AMI trial 49 Copegus ® ribavirin 49 evaluable subjects 49 efficacy tolerability 49 oral diclofenac 49 ROCKET AF 49 carboplatin paclitaxel 49 subcutaneous dose 49 thromboembolic complications 49 mg qd 49 decompensated liver disease 49 lixisenatide 49 Clinical Study 49 myelodysplastic syndromes MDS 49 Vicinium TM 49 Controlled Trial 49 Raloxifene Evaluation MORE 49 PEGylated interferon beta 1a 49 Adalimumab 49 Initiate Phase 48 IV bolus 48 mg subcutaneous injection 48 morphometric vertebral fractures 48 prospective observational cohort 48 Oral Fingolimod 48 paclitaxel poliglumex 48 Clolar ® 48 pharmacokinetic pharmacodynamic 48 polyarticular 48 alvimopan 48 Ophena TM 48 interferon alfa 2b 48 trials BLISS 48 selective androgen receptor modulator 48 Cerebral Amyloid Angiopathy 48 Sanofi Pasteur Fluzone 48 n = 48 inhaled corticosteroid ICS 48 metreleptin 48 LEVADEX 48 Mg Uk 48 generalized anxiety disorder GAD 48 chronic plaque psoriasis 48 Phase III randomized controlled 48 ABC/3TC 48 CARDIA study 48 omecamtiv mecarbil 48 methylnaltrexone bromide 48 REVLIMID lenalidomide 48 acute HAE attacks 48 investigational protease inhibitor 48 randomized multicenter Phase III 48 AEGR 48 diarrhea predominant irritable 48 refractory metastatic colorectal cancer 48 Tocilizumab 48 colesevelam HCl 48 Zerenex 48 NYHA Class II 48 IMiDs ® compound 48 capecitabine 48 interferon beta 1b 48 pramlintide 48 Atherosclerosis Risk 48 FOLFOX6 chemotherapy regimen 48 investigational compound 48 pharmacokinetic PK profile 48 bortezomib Velcade R 48 SORT OUT III 48 amoxicillin clavulanate 48 recurrent VTE 48 nucleotide analog 48 infliximab monotherapy 48 TEMODAL 48 comparing alemtuzumab 48 AIDS Clinical Trials 48 ACTIVE W 48 beclomethasone dipropionate 48 trastuzumab emtansine T DM1 48 Contrave# 48 PEGASYS ® 48 ISENTRESS 48 eptifibatide 48 leukemia AML 48 FOLFOX 48 dosing schedules 48 sorafenib Nexavar ® 48 solithromycin 48 metastatic GIST 48 placebo 48 LHON 48 RLAI 48 REGENESIS Phase IIb 48 Prostate AdenoCarcinoma Treatment 48 tocilizumab 48 PegIntron 48 Qnexa TM 48 unfractionated heparin UFH 48 hepatitis C HCV 48 RANK Ligand inhibitor 48 lanthanum carbonate 48 hour bronchodilation 48 RIO Lipids 48 piperacillin tazobactam 48 RezularTM 48 alvespimycin 48 KRAS mutations occur 48 candesartan cilexetil 48 juvenile idiopathic arthritis 48 Phase 2b clinical trials 48 virus HCV infection 48 mGluR2 positive 48 INVEGA ® 48 SomatoKine R 48 HPTN 48 Stenting Trial CREST 48 CHAMPION PCI 48 eosinophilic asthma 48 Kit CD# positive 48 Amrubicin 48 vinorelbine 48 pegylated liposomal doxorubicin 48 liver transplant recipients 48 investigational antiplatelet agent 48 Enzastaurin 48 equi analgesic doses 48 CCR5 mAb 48 UPLIFT 48 AIR2 Trial 48 CIMZIA R 48 ketolide antibiotic 48 TMC# [002] 48 intravenous RSD# 48 JANUVIA 48 opioid induced constipation 48 sulodexide 48 hypercalcemia 48 neovascular form 48 ataluren 48 Fx #A 48 CYT# 48 ILUVIEN ® 48 perampanel 48 Acute Ischemic Stroke 48 idiopathic Parkinson disease 48 dacarbazine 48 TAXUS TM 48 darunavir ritonavir 48 EOquin TM 48 fostamatinib 48 Young Adults CARDIA 48 CTAP# Capsules 48 toenail onychomycosis 48 dyslipidaemia 48 neurogenic orthostatic hypotension 48 Systemic Sclerosis 48 Phase IIb Trial 48 #mg doses [002] 48 Alzhemed TM 48 Dabigatran etexilate 48 Fibrillex TM 48 Safinamide 48 intravitreal insert 48 GOUT 48 urate lowering 48 CEL SCI Phase III 48 factorial design 48 buprenorphine naloxone 48 EFAPROXYN 48 Multicentre 48 relapsed APL 48 refractory chronic lymphocytic 48 BARI 2D 48 secondary endpoint 48 rosuvastatin #mg 48 Group RTOG 48 IIa clinical trials 48 zolmitriptan 48 COPEGUS 48 standard chemotherapy regimen 48 DermaVir Patch 48 subcutaneous enoxaparin 48 2 methoxyestradiol 48 Phase III metastatic melanoma 48 primary efficacy endpoint 48 Phase IIb randomized 48 dependent kinase inhibitor 48 orally administered 48 Forodesine HCl 48 diabetic peripheral neuropathic pain 48 unresectable recurrent 48 induced macular edema 48 FOLOTYN ® 48 albiglutide 48 metformin sulfonylurea 48 microgram kg 48 QD dosing 48 PET FROM 48 investigational monoclonal antibody 48 plus methotrexate 48 Bayer HealthCare Onyx Pharmaceuticals 48 patients evaluable 48 FOSRENOL R 48 Elacytarabine 48 ASH Abstract # 48 pharmacodynamic properties 48 direct thrombin inhibitor 48 Hypoactive Sexual Desire Disorder 48 Endovascular Valve Edge 48 Amigal 48 Dose escalation 48 DIRECT Trial 48 metformin HCl 48 eszopiclone 48 URTI 48 #.#mg/kg [002] 48 #mg QD [001] 48 flibanserin #mg 48 peritumoral brain edema 48 antiviral activity 48 HGS ETR1 48 Phase IIA 48 mg/m2 cohort 48 atherogenic dyslipidemia 48 pitavastatin 48 Naive Patients 48 intravenous bolus 48 ocular hypertension 48 PF # [001] 48 DASISION 48 WHIMS 48 patients undergoing CABG 48 randomized Phase 2b 48 citalopram 48 limiting toxicity DLT 48 longitudinal study 48 temozolomide 48 Laquinimod 48 pertuzumab 48 refractory prostate cancer 48 Phenoptin 48 unresectable HCC 48 omega interferon